Startups and Licensing
Intellectual property developed at the Wyss Institute is marketed by the Institute’s Business Development team, which works with Harvard’s Office of Technology Development to negotiate license agreements to existing companies or new startups. Some examples of our licensed technologies and startups are described below.
-
Manifold Bio
Multiplexed measurement for drug discovery
CloseManifold Bio
Building upon research done at the Wyss, Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement to development of protein therapeutics.
Translation News
Manifold Bio Raises Seed Round to Bring Massively Multiplexed Measurement to Drug Discovery
-
Metalmark
Nanostructured materials for air purification
CloseMetalmark
Metalmark is commercializing catalytic nanoarchitecture technology developed at the Wyss to make clean air available to all by creating super-efficient, catalysis-based air purifiers inspired by the nanoarchitecture of butterfly wings.
Translation News
-
Torus Biosystems
Point of care molecular diagnostics
CloseTorus Biosystems
Torus Biosystems™ leverages toehold DNA nanotechnology from the Wyss Institute to enable rapid, quantitative, and highly multiplexed detection of infectious disease pathogens and host immune-response markers, facilitating point-of-care precision diagnostics.
Translation News
-
Amend Surgical
Suture-less wound closure for oral surgery
CloseAmend Surgical
Amend Surgical is developing the Wyss Institute’s tough gel technology into a biocompatible adhesive that can be used to safely and effectively seal wounds after oral surgery, replacing uncomfortable and hard-to-sew sutures.
Translation News
Wyss Institute’s tough gel technology licensed to Amend Surgical for oral surgery applications
-
Ally Therapeutics
Solving the immune response barriers for gene therapy
CloseAlly Therapeutics
Ally Therapeutics licensed a technology that enables broader use of AAV gene therapies. Originally developed at the Wyss Institute, this technology improves both safety and efficacy of gene therapy, specifically by reducing innate immune responses against the DNA.
-
Rejuvenate Bio
Gene therapy for age-related diseases
CloseRejuvenate Bio
Rejuvenate Bio is developing a combination gene therapy technology from the Wyss Institute to create a treatment that stops the progression of Mitral Valve Disease and other age-related conditions in dogs
Translation News
Rejuvenate Bio launches to help dogs live longer, healthier lives
Harvard study advances gene therapy in fighting age-related diseases
A New Approach to Gene Therapy—Now In Dogs, Maybe Later In Humans
-
BOA Biomedical
Pathogen-capture
CloseBOA Biomedical
BOA Biomedical is developing a pathogen-capture technology that physically removes bacteria, viruses, and other infectious agents from the blood. This system has the potential to save lives by treating or preventing life-threatening sepsis, buying extra time for critically ill patients to fight off diseases, and quickly identify pathogens so patients can be given the right treatment, thereby reducing the development of antibiotic resistance.
Translation News
Wyss Institute and Miraki Innovation Unveil BOA Biomedical to Reduce Sepsis Deaths
-
Sherlock Biosciences
Molecular diagnostics
CloseSherlock Biosciences
Sherlock Biosciences leverages the INSPECTR™ technology from the Wyss Institute to create a highly sensitive, nucleic acid-based diagnostic platform that can rapidly deliver accurate and inexpensive results for a vast range of needs in virtually any setting
Translation News
Sherlock Biosciences Licenses Wyss Technology to Create Affordable Molecular Diagnostics
Gates Foundation backs 'instrument-free' molecular diagnostic tests through Sherlock, Mologic tie-up
FDA Authorizes First-Ever Crispr Application For COVID-19 Coronavirus Test
-
ReadCoor
Spatial sequencing
CloseReadCoor
ReadCoor leverages the Wyss Institute’s Fluorescent in situ Sequencing method for simultaneously sequencing and mapping thousands of RNAs within cells and tissues to advance development of diagnostics and discover new drug targets.
Translation News
Wyss Institute launches ReadCoor to commercialize 3D in situ gene sequencing technology
-
Ultivue
DNA-based Imaging
CloseUltivue
Ultivue is developing innovative imaging solutions to unfold new areas of biology by leveraging the Institute’s DNA-PAINT technology. At the center of the technology is the transient binding of fluorophores to targets mediated by DNA-DNA interaction
Translation News
Ultivue Raises $22 Million in Series C Funding
Ultivue Inc. Announces Completion of its Series B Financing
Harvard’s Wyss Institute launches Ultivue to facilitate super-resolution microscopy
-
FitBiomics
Sports genomics
CloseFitBiomics
FitBiomics utilizes next-generation sequencing to identify and isolate novel probiotic bacteria for applications in sports performance and recovery. Learn more about the Wyss Institute’s ‘Sports Genomics’ technology.
Translation News
Harvard’s athlete-based next-generation probiotics technology licensed to FitBiomics
Discovery of performance-enhancing bacteria in the human microbiome
-
Emulate
Organs-on-Chips
CloseEmulate
Emulate leverages the Wyss Institute’s organs-on-chips technology to emulate human biology towards understanding how diseases, medicines, chemicals, and foods affect human health
Translation News
Liver-Chip Identifies Distinct Drug Toxicities in Human, Rat, and Dog Models
Founders Fund Leads $36 Million Financing Round in Emulate, Inc.
Organ-On-A-Chip Startup, Emulate, Grabs $45M to Shake Up Drug Discovery
Wyss Institute’s technology translation engine launches ‘Organs-on-Chips’ company
Organs-on-Chips Centre opens in UK for advancements in medical research and drug development
Emulate Achieves 150 User Installations of Zoë® Instrument as a Lab-Ready Organs-on-Chips Platform